Junlin Healthcare Enterprise Development Update · Issue 7, 2024

Harbour BioMed Batoclimab

Listing Application Accepted

On July 18, 2024, the resubmitted marketing application for Harbour BioMed's Batoclimab injection was accepted by the NMPA for the treatment of generalized myasthenia gravis. According to the clinical trial protocol, Harbour BioMed has successfully completed the extension study of the Phase III clinical trial, collecting more long-term safety data without recruiting new patients. In 2021, Harbour BioMed's Batoclimab received Breakthrough Therapy Designation, and in March 2023, Harbour BioMed announced positive data from the Phase III clinical trial for generalized myasthenia gravis.

Abogen's mRNA Vaccine for COVID-19 Variants

Results of Phase III Clinical Study Published

Recently, Abogen, in collaboration with the Academy of Military Medical Sciences and the National Institutes for Food and Drug Control, along with multiple institutions domestically and internationally, published an article in Med, the flagship medical journal of Cell Press, on the Phase III clinical study of the mRNA vaccine (code name: ABO1020) targeting the BA.4/5 variants of COVID-19. This international multicenter Phase III clinical trial was conducted across 16 research centers in the UAE, Philippines, and Indonesia (such as Al Kuwait-Dubai (Al Baraha) Hospital, Philippine General Hospital, Persahabatan Hospital), aiming to evaluate the protective efficacy, immunogenicity, and safety of two doses of ABO1020 administered to populations previously vaccinated with two or three doses of inactivated COVID-19 vaccines. Results showed that despite the antigen sequence being designed for the S-RBD of the Omicron variant (BA.4/5), a high level of neutralizing antibodies against authentic XBB.1.5 virus (GMT=479) was generated after a single dose, and during the period when XBB and its sub-lineages were predominant, the vaccine demonstrated 94.86% effectiveness in protecting the elderly. In the context of the ongoing rapid mutations of the coronavirus, ABO1020 can effectively prevent symptomatic infections caused by variants. The successful completion of the international multicenter Phase III clinical study of ABO1020 indicates that the safety, efficacy, and large-scale production capabilities of Abogen's mRNA-LNP technology platform have been fully clinically validated, laying a solid foundation for the application of mRNA technology in other areas such as infectious disease prevention and treatment, cancer vaccines, and protein replacement therapies.

Prometheus Announces

PM8002 (anti-PD-L1/VEGF bispecific antibody) another indication

Approved for Pivotal Phase III Clinical Trial

PM Bioscience Announces that Its Self-Developed Anti-PD-L1/VEGF Bispecific Antibody New Drug PM8002 Injection has been Approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) to Conduct Another Pivotal Phase III Clinical Trial: A Multicenter, Open-Label, Randomized Phase III Clinical Study of PM8002 Injection in Combination with Paclitaxel Injection Versus Chemotherapy as Second-Line Treatment for Immune-Treated Small Cell Lung Cancer (SCLC). This is the second indication for which PM8002 has been approved for Phase III clinical trials following triple-negative breast cancer (TNBC). PM8002 is a bispecific antibody drug composed of a humanized anti-PD-L1 single-domain antibody (VHH) fused to an anti-VEGF-A IgG1 antibody containing Fc-silencing mutations. It is currently being evaluated in multiple clinical studies across various tumor types in China, including triple-negative breast cancer, small cell lung cancer, non-small cell lung cancer, and cervical cancer, with related clinical data being released at academic conferences such as SABCS, ESMO, and ASCO.

The First in China to Enter Human Clinical Research (IIT)

Rui Zheng Gene In Vivo Gene Editing New Drug ART001

Granted CDE Class 1 New Drug Clinical Approval

ART001, an innovative drug independently developed by Rui Zheng Gene (Suzhou) Co., Ltd. for the treatment of transthyretin amyloidosis (ATTR), is the first non-viral vector in vivo gene-editing drug in China to enter human clinical research (IIT). On July 19, 2024, it was approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) to commence clinical trials. ART001 initiated the first human clinical research (IIT) in China for an in vivo gene-editing product based on a non-viral vector in August 2023. Currently, all subjects have completed at least 24 weeks of follow-up. TTR protein levels decreased by over 90% from baseline as early as four weeks after dosing and remained stable after 24 weeks, with no off-target editing observed. Based on the safety and efficacy data obtained so far, ART001 has reached a world-class level within the industry.

ART001 will soon apply for the U.S. (FDA) IND and has the potential to become the first non-viral vector in vivo gene editing product from China to undergo dual filing in both China and the U.S.

Abogen Shingles IN001

mRNA Vaccine Receives Clinical Trial Approval in China

Hong Kong, Shenzhen, Nanjing - July 23, 2024 — Innorna, a biopharmaceutical company focusing on lipid nanoparticle (LNP) delivery technology and the development of innovative RNA therapies, announced that its self-developed IN001 mRNA vaccine for shingles has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration (NMPA). IN001 is the first shingles vaccine using the mRNA technology platform to receive clinical trial approval from the NMPA, and it is also the second vaccine product developed by Innorna to receive clinical trial approval in China, following the respiratory syncytial virus IN006 bivalent mRNA vaccine. IN001 obtained Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) in September 2023, making it the third shingles vaccine globally, after Moderna and Pfizer/BioNTech, to receive FDA clinical trial authorization using the mRNA technology platform. Innorna has initiated Phase I clinical research (NCT06375512) with healthy volunteers outside of China and will soon commence domestic clinical trials following the receipt of clinical trial approval in China, aiming to bring this potentially safer, more effective, and accessible shingles vaccine to the Chinese and global markets as soon as possible for the benefit of the public.

Langxin Bio Gene Therapy Class 1 New Drug

Proposed for inclusion in the breakthrough therapy category

On July 22, 2024, the official website of the Center for Drug Evaluation (CDE) under China's National Medical Products Administration (NMPA) announced that LX101 Injection, submitted by Shanghai Langsheng Biotechnology (a subsidiary of Langxin Biotechnology), has been proposed for inclusion in the breakthrough therapy designation. It is intended for treating patients with inherited retinal dystrophy (IRD) associated with biallelic RPE65 mutations. Public data indicates that LX101 Injection is a gene therapy drug using rAAV as a vector, and its treatment for RPE65 mutation-related IRD has entered Phase 3 clinical trials. LX101 is a gene therapy drug developed by Shanghai Langsheng Biotechnology for hereditary retinal degeneration. The drug uses adeno-associated virus serotype 2 (AAV2) to carry the normal RPE65 gene, specifically recognizing and transfecting diseased retinal pigment epithelial cells, enabling continuous and efficient expression of the RPE65 protein, which patients lack, restoring normal visual cycles and achieving the therapeutic goal of improving visual function. In previously conducted investigator-initiated clinical studies, LX101 demonstrated good safety and has shown efficacy in improving vision in multiple patients.

DeepTrust Bio mRNA Drug IN022

Granted FDA Orphan Drug Designation

On July 19, 2024, Abogen announcedAbogen's mRNA New Drug IN022 Receives FDA Orphan Drug Designation Following Rare Pediatric Disease Designation. IN022 is used for treating Homocystinuria (HCU), an autosomal recessive inherited metabolic disorder. Obtaining both RPDD and ODD will significantly accelerate the clinical development and market launch of IN022, benefiting patients sooner.

Etana Indonesia Localization

Bevacizumab, 13-valent pneumococcal conjugate vaccine approved

Expected to Become Indonesia's Exclusive Medical Insurance Product

Recently, PT Etana Biotechnologies Indonesia (ETANA), an Indonesian biotechnology company, has completed localized large-scale production and received approval from Indonesia's Food and Drug Supervisory Agency (BPOM) for two products: Bevagen (Bevacizumab Injection, Indonesian trademark: Bevagen), technology-transferred from Chinese pharmaceutical companies Innovent Biologics and Walvax Biotechnology, and the 13-valent pneumococcal polysaccharide conjugate vaccine (Chinese trade name "Walrixin" / Indonesian trade name "VALENINA," hereinafter referred to as "13-valent pneumococcal conjugate vaccine" or "PCV-13"). These approvals aim to meet the growing demand of Indonesia's pharmaceutical market. This marks a milestone as the first locally produced antibody drug and vaccine product approved in Indonesia. It also signifies that after the technology transfer of antibody and vaccine products by Chinese pharmaceutical companies to Southeast Asia, their locally manufactured products have gained official recognition in Indonesia for the first time. The achievement highlights the deep collaboration and shared progress between both parties in the biopharmaceutical field, ushering in a new era for Chinese pharmaceutical enterprises expanding into Southeast Asia.

Saifu Guotong (Wuxi) CDMO to CRO

Integrated Nuclear Medicine R&D Service Platform Officially Launched

On July 12, 2024, at the Nuclear Medicine Full Industry Chain Development Cooperation Forum during the 20th Anniversary Meeting of Tongxieyi, the "Precious 'Nuclear'—Saifu-Guotong (Wuxi) CDMO to CRO Integrated Nuclear Medicine R&D Service Platform," jointly established by Saifu Pharmaceutical and Guotong New Drug, was officially launched. Wuxi Saifu-Guotong Pharmaceutical Technology Co., Ltd., with full medical radionuclide usage qualifications, provides integrated production and R&D technical services for radiopharmaceuticals (CRDMO) in compliance with FDA, NMPA, and OECD regional/regulatory requirements. These services span from production to non-clinical and clinical stages, including CDMO, pharmacology/toxicology, drug metabolism, isotope molecular imaging, and mass balance studies. Saifu-Guotong (Wuxi) holds a Class B unsealed radioactive material workplace qualification and can conduct experiments related to 40 types of radioactive isotopes, such as 18F, 68Ga, 177Lu, 89Zr, 131I, 99mTc, 14C, and 125I. It offers professional and reliable one-stop services for radiopharmaceutical and innovative drug development companies.

Academician Ge Junbo's Team Successfully Completes

Puchuang Medical Sonico-CX® Intravascular Shock Wave Treatment System

First Application Nationwide After Market Launch

Recently, Professor Ge Lei and Professor Lu Hao from the team of Academician Ge Junbo at Zhongshan Hospital Affiliated to Fudan University successfully completed the first two clinical applications of the Puchuang Medical Sonico-CX® Intravascular Shockwave Treatment System after its market launch. The successful completion of the surgeries not only fully demonstrated the robust capabilities of China-produced intravascular shockwave treatment systems in addressing complex and severe calcified lesions but also marked that interventional doctors across China will now be equipped with safer and more efficient domestically produced innovative devices to safeguard the health of patients with coronary artery calcification, offering new hope for their well-being. Puchuang Medical Technology (Shanghai) Co., Ltd., established in 2019, is headquartered in Shanghai and has an overseas R&D center. It is a platform-based innovative medical technology enterprise specializing in active minimally invasive interventional technologies for cardiac and peripheral vascular applications. The company holds multiple patents both domestically and internationally, has five new products under development, and has been recognized as a National High-tech Enterprise.

Cloud Boat Bio mRNA Delivery

Technology Transfer Platform Officially Launched

Broad prospects for the future

Recently, Cloud Boat Biotech officially launched its mRNA delivery technology transformation platform located in Guangzhou Creator Park to better provide customized clinical-grade mRNA products for global customers. The base covers an area of approximately 1600m².², planning three major areas: technology research and development, process development, and GMP production, of which approximately 1000m²Built according to GMP standards, it is equipped with flexible production equipment such as single-use bioreactors, single-use chromatography systems, single-use ultrafiltration systems, and single-use LNP encapsulation systems. It aims to create a translational platform that can quickly respond to the personalized development needs of mRNA vaccines and drugs. As a world-leading full-chain service provider in gene delivery, Cloud舟 Biotech has successively established four major R&D and production bases in Guangzhou: an incubator base (gene delivery R&D platform), Haisha and Najin bases (gene delivery production platforms), and the Creator Base (mRNA delivery technology translational platform). The launch of the Creator Base will further enhance Cloud舟 Biotech's gene delivery industry chain layout, improve its mRNA business capabilities, and bring new growth opportunities for the company’s operations. Meanwhile, as a leading mRNA service platform in the Guangdong-Hong Kong-Macao Greater Bay Area capable of providing both CRO and CDMO services, it will more comprehensively meet the diverse needs of innovative enterprises and provide strong support to the global biopharmaceuticals industry.

KingMed Scores Full Marks

China National Proficiency Testing for mNGS in Central Nervous System Infections

Recently, the National Center for Clinical Laboratories (NCCL) of the National Health Commission of China announced the results of the 2024 pre-research activity for inter-laboratory quality evaluation of metagenomic high-throughput sequencing for central nervous system infections in China. Beijing Shengquan Gene Medical Laboratory, a wholly-owned subsidiary of Gensee Medicine, achieved a perfect score in this external quality assessment. Additionally, all 30 medical institutions collaborating with Gensee Medicine successfully passed the assessment with either perfect or high scores. Based on its Molecular Cube Lab© localized solution and strict management system, Gensee Medicine’s medical testing laboratories have consistently excelled in multiple external quality assessments initiated by the NCCL over the past four years, demonstrating the company's high-standard testing capabilities and stable laboratory management system in the detection of blood, respiratory, and cerebrospinal fluid samples.

Baiyang Pharmaceutical Group

Joining Hands with ZAP, the Global Giant in Radiation Therapy Technology

Jointly Promote the Innovation of Radiation Therapy Technology

On July 22, 2024, Baiyang Pharmaceutical Group signed a significant strategic cooperation agreement with ZAP Surgical, a global leader in radiosurgery robotic technology. The collaboration includes equity investment, large-scale production, and commercial operation of ZAP's core product, the ZAP-X® Mars Boat Radiosurgery Robot. Previously, Baiyang had already made substantial investments in the medical linear accelerator sector, incubating China’s first X-band 4π intelligent robotic radiotherapy system. Following this partnership with ZAP, they will establish international competitiveness in precision radiotherapy. The ZAP-X® Mars Boat Radiosurgery Robot is the world's first radiation therapy device with self-shielding capabilities. This equipment was registered and launched in the United States in September 2017. In 2018, ZAP-X received special approval through China’s Innovative Medical Device Review Process, and in 2019, it was installed at the PLA General Hospital for clinical trial research. On June 20, 2023, the device was officially approved for marketing in China.

Innovent Biologics Deepens Strategic Cooperation with IASO Biotherapeutics

Join Hands to Promote Innovative Development in the Field of Cell Therapy Drugs

July 5, 2024, San Francisco, USA, and Suzhou, China — Innovent Biologics Group (Stock Code: 01801.HK), a biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative drugs in major disease areas such as oncology, autoimmune diseases, metabolic disorders, cardiovascular diseases, and ophthalmology, and IASO Biotherapeutics, a biopharmaceutical company focused on the R&D, manufacturing, and commercialization of innovative cell therapies, jointly announced today that they have signed a series of cooperation agreements. The agreements cover IASO Biotherapeutics' acquisition of revenue rights and intellectual property licenses for the collaborative product Focusa® from Innovent Biologics, as well as Innovent Biologics' equity investment in IASO Biotherapeutics. According to the terms of the agreement, IASO Biotherapeutics will purchase the relevant rights owned by Innovent Biologics under the original BCMA CAR-T collaboration agreement at an agreed price. Meanwhile, Innovent Biologics will invest in IASO Biotherapeutics at the same price and hold 18% of the company's shares after the investment. Under the new strategic cooperation framework, both parties will achieve a high level of resource integration in the field of cellular immunotherapy. IASO Biotherapeutics will obtain global commercialization rights and intellectual property licenses for Focusa® (Equecabtagene Autoleucel Injection) and will independently oversee and make decisions regarding the product’s development, manufacturing, and commercialization. At the same time, Innovent Biologics will become a strategic shareholder of IASO Biotherapeutics. Focusa® (Equecabtagene Autoleucel Injection), co-developed by Innovent Biologics and IASO Biotherapeutics, was officially approved by the National Medical Products Administration (NMPA) on June 30, 2023. It is the world's first commercially available fully human CAR-T product, China's first self-developed and fully self-manufactured CAR-T cell therapy, the first domestically approved BCMA-targeted CAR-T product, and the first cell therapy product in China approved for the treatment of multiple myeloma.

Dingkang Medical and Medtronic

Further Strategic Cooperation

Collaborative Empowerment Accelerates the Landing of Innovative Products

On July 1, 2024, Dibond Medical Technology (Suzhou) Co., Ltd. and Medtronic (Shanghai) Management Co., Ltd. held a grand second-phase strategic cooperation signing ceremony in Suzhou Industrial Park. This marks the further upgrading of their cooperative relationship since the signing of the strategic cooperation agreement for the coronary drug-coated balloon project in 2022, ushering in a new starting point for collaboration. Based on a long-term strategic partnership, the two parties will comprehensively cooperate in promoting the Diamond Coronary Scoring Balloon Dilatation Catheter product in the Chinese market, accelerating the commercialization process of this product across China, and jointly exploring deeper directions of cooperation in the coronary field. Founded in 2015, Dibond Medical is a high-tech company specializing in the research, development, and production of vascular interventional medical treatment products, committed to continuous innovation, excellence, and high-quality manufacturing. Dibond Medical is dedicated to addressing the complex challenges of current diseases, with its business lines mainly covering coronary intervention, peripheral intervention, and neurointervention fields, providing corresponding solutions.

ClinChoice Kunling Partners with Jaffray Capital in Strategic Collaboration

Supporting the Overseas Expansion of China's Innovative Drugs

Recently, ClinChoice Kunling has reached a strategic cooperation with Joffre Capital. Both parties will leverage their respective strengths to deepen multi-dimensional cooperation, focusing on jointly building an international incubator platform, supporting the overseas strategy of China's innovative drugs, facilitating cross-border business and transactions for pharmaceutical companies at home and abroad, and creating greater value for customers' sustainable development.

ClinChoice Kunling, as a globally-deployed clinical CRO, is always committed to providing full services and professional solutions throughout the entire R&D lifecycle for local and global pharmaceutical, biopharmaceutical, medical device, and consumer health companies. Focusing on industry development and meeting customer needs, the company has successively acquired CROMSOURCE, a European clinical CRO headquartered in Italy, and CSI, a Southeast Asian clinical CRO based in Singapore, continuously expanding its international presence while deepening and perfecting its professional expertise and teams. This strengthens its ability and potential to deliver professional services to clients worldwide.

Jaffa Capital is a new type of investment and investment banking consultancy dedicated to biopharmaceutical investment and financing, cross-border asset transactions, and asset incubation in China and overseas. Its global transaction team covers major global pharmaceutical innovation regions including the United States, Japan, and Europe. Over the past decade, it has successfully facilitated numerous overseas projects entering the Chinese market and assisted many Chinese products in completing overseas licensing.

BioMap and BioRay Biologics Joint Innovation

AI-Driven AAV Solutions

Leading a New Era of Gene Therapy

Since November 2023, BioMap announced a strategic partnership with Porton Advanced. Both parties have been committed to leveraging cutting-edge large-scale life science models to assist in the development of algorithms related to adeno-associated virus (AAV). After six months of close collaboration, BioMap and Porton Advanced reached a significant milestone in July 2024 — successfully launching an AI-driven AAV solution, ushering in a new chapter for gene therapy. Based on BioMap’s AIGP platform and xTrimoPGLM large model, combined with Porton Advanced’s extensive expertise in AAV libraries and experimental validation, the two companies have built an efficient and precise one-stop AAV library design service. This innovative achievement enables users to efficiently design and optimize AAV libraries covering more than 10 serotypes, including point mutations, short peptide insertions, and fragment recombination, to achieve higher transduction efficiency, tissue and organ specificity, and immune escape capabilities. The success of this collaboration marks an important developmental stage for the AAV design field. By integrating AI technology with biopharmaceutical practices, BioMap and Porton Advanced have not only greatly improved the efficiency and success rate of AAV screening but also provided a powerful tool and solid support for research and application in the fields of gene therapy and biomedicine.

Multiple medical and health companies invested in by Legend Capital

Ranked on the 2024 Future Healthcare Technology Leaders List

"Shining 100" and "Brilliant 100"

From July 4 to 5, 2024, the 2024 Future Medical Technology Conference was grandly held at the Beijing Zhongguancun Dongsheng Science Park. At the same time, the two authoritative lists of 2024 Future Medical Technology Leaders, "Shining 100" and "Brilliant 100," were震撼 released. Several medical and health enterprises invested by Legend Capital won multiple awards.

Shining 100 Diagnostic Assistance

•Di Yingjia

•United Mind Medical

•Deepwise Healthcare

Shining 100 Drug Development

•N1 Life

•BioMap

•Pharmaron

• ZK Bio

Brilliant 100 Biological Testing

•King's Medicine

•Hanchen Light Wing

• Micro-Nano Core

• Unknown Jun

Brilliant 100 Chemical Pharmaceutical

•Qingpu Bio

Pins Medical Honored with Global Innovative Medical Device Award

Recently, the first Global Medical Technology Conference and Global Biomedical Conference, guided by the Zhongguan Village Science City Management Committee and jointly organized by Siyu MedTech and the Zhongguan Village Lianxin Biomedical Industry Alliance, was held at the Exhibition Center Conference Center of Zhongguan Village Independent Innovation Demonstration Zone in Beijing. At the membership awarding ceremony of the Zhongguan Village Lianxin Biomedical Industry Alliance and the 2024 Global Medical Technology Awards Ceremony, PINS Medical won the Global Innovative Medical Device Award with its latest directional deep brain stimulation system. The winning product is the innovative directional stimulation system developed by Beijing PINS Medical Device Co., Ltd., approved by NMPA on May 28, 2024. This marks the official entry into the market of China's first directional deep brain stimulation product. Beijing PINS Medical Device Co., Ltd. is a high-tech enterprise specializing in the research, production, and sales of a series of neuromodulation products, including brain pacemakers, vagus nerve stimulators, spinal cord stimulators, and sacral nerve stimulators. It is the only company in the world that owns these four mainstream series of neuromodulation products, dedicated to providing advanced treatment options for patients with functional neurological disorders such as Parkinson’s disease, epilepsy, pain, and urinary incontinence. In 2023, PINS Medical was recognized as a National Enterprise Technology Center. As of June 2024, the total number of implants across all product lines has exceeded 34,000 cases, covering nearly 700 hospitals in China, making it a pioneer and leader in China's neuromodulation industry.

AccuraBio Honored with Global MedTech Pioneer Award

Recently, at the 1st Global Medical Technology Conference and Global Biomedical Conference hosted by the Zhongguan Village Lianxin Biomedical Industry Alliance, Colorful Biotech was awarded the Global Medical Technology Rising Star Award for its self-developed single-molecule detection platform's outstanding performance in Alzheimer's disease testing. The single-molecule detection platform independently developed by Colorful Biotech has demonstrated ultra-sensitive, high-precision, digital, and intelligent features in Alzheimer’s disease testing. With a sensitivity level of fg/mL, the platform surpasses traditional methods by a thousandfold, offering significant clinical value for risk warning and early detection. Utilizing blood tests, the platform provides advantages such as being non-invasive, low-cost, and highly acceptable to patients, overcoming the limitations of traditional testing methods like lumbar punctures and PET-CT scans. It is suitable for large-scale population screening and contributes to the early screening, diagnosis, and treatment of Alzheimer's disease. Colorful Biotech has been committed to providing precise diagnosis and treatment solutions for patients in China. Through continuous technological innovation and product upgrades, it injects new momentum into the development of China’s healthcare industry.

Beijing Neurosurgical Institute

Awarded the Gold Medal for Invention Patent in Geneva

Beichuo Medical Undertakes Technology Transfer

Recently, the patent technology "A Radiomics Prediction Method for Gene Expression Levels in Gliomas" transferred from the Beijing Neurosurgical Institute to Beizhuo Medical won the Gold Medal at the Geneva Invention Exhibition. The Geneva International Exhibition of Inventions, established in 1973, is jointly organized by the Swiss Federal Government, the Geneva State Government, the City of Geneva, and the World Intellectual Property Organization (WIPO). It is one of the oldest, largest, and most authoritative invention exhibitions globally. The original research achievement, "A Radiomics Prediction Method for Ki-67 Expression Levels in Gliomas," by Academician Jiang Tao and Professor Wang Yinyan's research team from the Beijing Neurosurgical Institute, stood out among over 1,000 technological inventions from 47 countries and regions worldwide, winning the Gold Award at the 49th International Exhibition of Inventions in 2024. This innovative technology, which received a national invention patent in China in 2022, allows for the non-invasive prediction of the expression levels of the key molecular marker Ki-67, closely related to tumor malignancy, based on preoperative magnetic resonance imaging, thereby guiding personalized precision treatment for gliomas. After the patent was granted, Beijing Beizhuo Medical Technology Development Co., Ltd. signed a technology transfer contract with the Beijing Neurosurgical Institute. Currently, this patented technology has been integrated into the glioma-assisted resection function module of surgical navigation products.